Autolus Therapeutics (AUTL) Competitors

$1.59 -0.12 (-7.02%)

Closing price 04:00 PM Eastern

Extended Trading

$1.60 +0.00 (+0.31%)

As of 04:44 PM Eastern

AUTL vs. NUVB, DMRA, HROW, ATAI, and IOVA

Should you buy Autolus Therapeutics stock or one of its competitors? MarketBeat compares Autolus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Autolus Therapeutics include Nuvation Bio (NUVB), Damora Therapeutics, Inc. Common Stock (DMRA), Harrow (HROW), Atai Beckley (ATAI), and Iovance Biotherapeutics (IOVA). These companies are all part of the "pharmaceutical products" industry.

How does Autolus Therapeutics compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

Nuvation Bio has higher earnings, but lower revenue than Autolus Therapeutics. Nuvation Bio is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	26.05	-$204.63M	-$0.43	N/A
Autolus Therapeutics	$75.39M	5.61	-$287.53M	-$1.08	N/A

Nuvation Bio has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market.

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Nuvation Bio has a net margin of -102.06% compared to Autolus Therapeutics' net margin of -381.40%. Nuvation Bio's return on equity of -44.10% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
Autolus Therapeutics	-381.40%	-99.05%	-42.31%

Nuvation Bio presently has a consensus price target of $12.50, indicating a potential upside of 165.67%. Autolus Therapeutics has a consensus price target of $8.75, indicating a potential upside of 450.31%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

In the previous week, Autolus Therapeutics had 1 more articles in the media than Nuvation Bio. MarketBeat recorded 7 mentions for Autolus Therapeutics and 6 mentions for Nuvation Bio. Autolus Therapeutics' average media sentiment score of 0.45 beat Nuvation Bio's score of 0.16 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Autolus Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Autolus Therapeutics beats Nuvation Bio on 9 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Autolus Therapeutics (NASDAQ:AUTL) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Autolus Therapeutics has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

Autolus Therapeutics currently has a consensus price target of $8.75, indicating a potential upside of 450.31%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $43.40, indicating a potential upside of 81.74%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Autolus Therapeutics is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -381.40%. Autolus Therapeutics' return on equity of -99.05% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-381.40%	-99.05%	-42.31%
Damora Therapeutics, Inc. Common Stock	N/A	-147.05%	-247.50%

In the previous week, Autolus Therapeutics had 3 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 7 mentions for Autolus Therapeutics and 4 mentions for Damora Therapeutics, Inc. Common Stock. Autolus Therapeutics' average media sentiment score of 0.45 beat Damora Therapeutics, Inc. Common Stock's score of 0.07 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Damora Therapeutics, Inc. Common Stock has lower revenue, but higher earnings than Autolus Therapeutics. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	5.61	-$287.53M	-$1.08	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$12.10	N/A

Summary

Autolus Therapeutics beats Damora Therapeutics, Inc. Common Stock on 13 of the 15 factors compared between the two stocks.

How does Autolus Therapeutics compare to Harrow?

Autolus Therapeutics (NASDAQ:AUTL) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Autolus Therapeutics has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market. Comparatively, Harrow has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 12.8% of Harrow shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Harrow has higher revenue and earnings than Autolus Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	5.61	-$287.53M	-$1.08	N/A
Harrow	$268.68M	4.28	-$5.14M	-$0.41	N/A

Autolus Therapeutics currently has a consensus price target of $8.75, indicating a potential upside of 450.31%. Harrow has a consensus price target of $69.43, indicating a potential upside of 124.98%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Harrow has a net margin of -5.57% compared to Autolus Therapeutics' net margin of -381.40%. Harrow's return on equity of 19.59% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-381.40%	-99.05%	-42.31%
Harrow	-5.57%	19.59%	2.26%

In the previous week, Harrow had 7 more articles in the media than Autolus Therapeutics. MarketBeat recorded 14 mentions for Harrow and 7 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.45 beat Harrow's score of -0.10 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harrow	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Autolus Therapeutics beats Harrow on 9 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

Atai Beckley has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market.

Autolus Therapeutics has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	362.43	-$660.05M	-$2.30	N/A
Autolus Therapeutics	$75.39M	5.61	-$287.53M	-$1.08	N/A

28.4% of Atai Beckley shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 26.8% of Atai Beckley shares are owned by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Autolus Therapeutics had 1 more articles in the media than Atai Beckley. MarketBeat recorded 7 mentions for Autolus Therapeutics and 6 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 1.25 beat Autolus Therapeutics' score of 0.45 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Autolus Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Autolus Therapeutics has a net margin of -381.40% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Autolus Therapeutics	-381.40%	-99.05%	-42.31%

Atai Beckley presently has a consensus price target of $14.63, indicating a potential upside of 262.00%. Autolus Therapeutics has a consensus price target of $8.75, indicating a potential upside of 450.31%. Given Autolus Therapeutics' higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

Autolus Therapeutics beats Atai Beckley on 10 of the 16 factors compared between the two stocks.

How does Autolus Therapeutics compare to Iovance Biotherapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and Iovance Biotherapeutics (NASDAQ:IOVA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

Iovance Biotherapeutics has a net margin of -123.92% compared to Autolus Therapeutics' net margin of -381.40%. Iovance Biotherapeutics' return on equity of -50.17% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-381.40%	-99.05%	-42.31%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Autolus Therapeutics has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Autolus Therapeutics presently has a consensus price target of $8.75, suggesting a potential upside of 450.31%. Iovance Biotherapeutics has a consensus price target of $8.43, suggesting a potential upside of 139.45%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Autolus Therapeutics is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

Autolus Therapeutics has higher earnings, but lower revenue than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	5.61	-$287.53M	-$1.08	N/A
Iovance Biotherapeutics	$285.61M	5.50	-$390.98M	-$0.95	N/A

In the previous week, Iovance Biotherapeutics had 10 more articles in the media than Autolus Therapeutics. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 7 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.45 beat Iovance Biotherapeutics' score of 0.26 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Iovance Biotherapeutics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Autolus Therapeutics beats Iovance Biotherapeutics on 9 of the 16 factors compared between the two stocks.

Get Autolus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AUTL vs. The Competition

Export

Metric	Autolus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$423.17M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-1.47	18.81	20.87	25.61
Price / Sales	5.61	181.76	521.62	63.45
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	2.37	6.75	9.86	6.71
Net Income	-$287.53M	$24.11M	$3.55B	$333.77M
7 Day Performance	-0.93%	0.11%	-0.26%	0.40%
1 Month Performance	7.43%	0.87%	1.39%	4.03%
1 Year Performance	30.33%	78.18%	41.07%	36.33%

Autolus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AUTL Autolus Therapeutics	3.3917 of 5 stars	$1.59 -7.0%	$8.75 +450.3%	+34.6%	$423.17M	$75.39M	N/A	330	News Coverage Earnings Report Analyst Forecast Gap Down
NUVB Nuvation Bio	3.0697 of 5 stars	$4.45 -0.9%	$11.63 +161.2%	+118.5%	$1.56B	$62.90M	N/A	60	High Trading Volume
DMRA Damora Therapeutics, Inc. Common Stock	2.384 of 5 stars	$25.93 +2.2%	$43.40 +67.4%	+765.9%	$1.53B	N/A	N/A	40	Earnings Report
HROW Harrow	3.2627 of 5 stars	$40.20 -1.7%	$69.86 +73.8%	+13.6%	$1.52B	$272.30M	N/A	180	News Coverage Earnings Report Analyst Forecast
ATAI Atai Beckley	3.9792 of 5 stars	$4.20 +1.4%	$14.63 +248.2%	+200.7%	$1.52B	$4.09M	N/A	80	Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AUTL) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Autolus Therapeutics (AUTL) Competitors

AUTL vs. NUVB, DMRA, HROW, ATAI, and IOVA

How does Autolus Therapeutics compare to Nuvation Bio?

Summary

How does Autolus Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Autolus Therapeutics compare to Harrow?

Summary

How does Autolus Therapeutics compare to Atai Beckley?

Summary

How does Autolus Therapeutics compare to Iovance Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Autolus Therapeutics (AUTL) Competitors

AUTL vs. NUVB, DMRA, HROW, ATAI, and IOVA

How does Autolus Therapeutics compare to Nuvation Bio?

Which has preferable earnings and valuation, NUVB or AUTL?

Which has more risk and volatility, NUVB or AUTL?

Do institutionals and insiders believe in NUVB or AUTL?

Is NUVB or AUTL more profitable?

Do analysts prefer NUVB or AUTL?

Does the media prefer NUVB or AUTL?

Summary

How does Autolus Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Do insiders & institutionals believe in AUTL or DMRA?

Which has more risk and volatility, AUTL or DMRA?

Do analysts prefer AUTL or DMRA?

Is AUTL or DMRA more profitable?

Does the media favor AUTL or DMRA?

Which has higher earnings & valuation, AUTL or DMRA?

Summary

How does Autolus Therapeutics compare to Harrow?

Which has more volatility & risk, AUTL or HROW?

Do institutionals & insiders believe in AUTL or HROW?

Which has better earnings and valuation, AUTL or HROW?

Do analysts prefer AUTL or HROW?

Is AUTL or HROW more profitable?

Does the media favor AUTL or HROW?

Summary

How does Autolus Therapeutics compare to Atai Beckley?

Which has more risk & volatility, ATAI or AUTL?

Which has higher valuation & earnings, ATAI or AUTL?

Do institutionals and insiders have more ownership in ATAI or AUTL?

Does the media prefer ATAI or AUTL?

Is ATAI or AUTL more profitable?

Do analysts recommend ATAI or AUTL?

Summary

How does Autolus Therapeutics compare to Iovance Biotherapeutics?

Is AUTL or IOVA more profitable?

Do insiders & institutionals have more ownership in AUTL or IOVA?

Which has more volatility and risk, AUTL or IOVA?

Do analysts recommend AUTL or IOVA?

Which has stronger valuation and earnings, AUTL or IOVA?

Does the media prefer AUTL or IOVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools